ema401造句

• EMA401 reaches a maximum plasma concentration of 1000 ug / L one-hour after administration of 100 mg of EMA401 in both men and women, as observed in a phase II trial.
• It is possible that a small amount of EMA401 is crossing the blood-brain barrier and affecting some functions of the CNS in the few patients that showed side-effects to EMA401.
• It is possible that a small amount of EMA401 is crossing the blood-brain barrier and affecting some functions of the CNS in the few patients that showed side-effects to EMA401.
• EMA401 had an IC of 39 nM for human ATR, compared to EMA402 with an IC of 1, 100 nM for human ATR . EMA401 was selected as the candidate drug for neuropathic pain treatment for clinical development.
• EMA401 had an IC of 39 nM for human ATR, compared to EMA402 with an IC of 1, 100 nM for human ATR . EMA401 was selected as the candidate drug for neuropathic pain treatment for clinical development.
• In consideration of the fact that the renin-angiotensin system regulates pressure within the cardiovascular system, patients taking EMA401 did not show any difference in vital signs or 12-lead ECG assessments compared to the patients taking placebo.
• EMA400 had an IC of 75.2 nM for rat ATR and an IC of 2.9x10 nM for rat ATR . EMA400, a racemate, was separated into EMA401, the S-enantiomer of EMA400, and EMA402, the R-enantiomer of EMA400.
• Spinifex Pharmaceuticals reported the results of a phase 2 clinical trial results in which 183 patients with postherpetic neuralgia received either oral EMA401 or placebo for 28 days . Those assigned to the active condition receiving EMA401 reported significantly less postherpetic neuralgia, a chronic neuropathic pain, compared to those in the placebo condition.
• Spinifex Pharmaceuticals reported the results of a phase 2 clinical trial results in which 183 patients with postherpetic neuralgia received either oral EMA401 or placebo for 28 days . Those assigned to the active condition receiving EMA401 reported significantly less postherpetic neuralgia, a chronic neuropathic pain, compared to those in the placebo condition.
• Inventors at Warner-Lambert Company LLC substituted 1, 2, 3, 4-tetrahydroisoquinoline with various functional groups to create numerous compounds of formula I that had improved affinity for ATR . EMA400, the racemate drug to EMA401, was originally Compound 6, one of the 48 compounds of formula I . Compound 6 had higher binding affinity for ATR, compared to the other 48 compounds, with an IC value of 2.8 nM in a rabbit uterus binding assay.
• It was also inactive in the ATR binding assay at concentrations of 10-5 M, suggesting high selectivity for ATR . Example 47, the S-enantiomer of Compound 6 and later named EMA401, was at the time an unanalyzed compound of formula I . Compound 6, under the name PD-126, 055, and five other ATR antagonists ( PD-123, 319, L-159, 686, PD-121, 981, L-161, 638 and L-163, 579 ) were reported to have previously unknown analgesic properties by investigators from the University of Queensland.